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This review will focus on recent knowledge related to circulating autoantibodies (AAbs) to tumor-associated antigens (TAAs)
in epithelial ovarian carcinoma. So far, the following TAAs have been identiﬁed to elicit circulating AAbs in epithelial ovarian
carcinoma:p53,homeoboxproteins(HOXA7,HOXB7),heatshockproteins(HSP-27,HSP-90),cathepsinD,cancer-testisantigens
(NY-ESO-1/LAGE-1), MUC1, GIPC-1, IL-8, Ep-CAM, and S100A7. Since AAbs to TAAs have been identiﬁed in the circulation
of patients with early-stage cancer, it has been speculated that the assessment of a panel of AAbs speciﬁc for epithelial ovarian
carcinoma TAAs might hold great potential as a novel tool for early diagnosis of epithelial ovarian carcinoma.
Copyright © 2009 B. Piura and E. Piura. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
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1.Introduction
The development of circulating autoantibodies (AAbs) to
tumor-associated antigens (TAAs) has been observed to
be associated with cancer [1, 2]. Unlike traditional tumor
markers (e.g., CA-125, CA-15-3, CA-19-9, and CEA), which
are soluble proteins shed by bulky tumors, circulating AAbs
to TAAs are detectable even when the tumor is very small
and TAA expression is minimal [2]. Thus, the identiﬁcation
of AAbs to TAAs could potentially be used as a novel tool for
early diagnosis of cancer [2–6]. Sahin et al. [7] introduced
in 1995 an approach that has broad applicability to the
analysis of the humoral immune response to cancer. This
method, called SEREX (serological analysis of recombinant
cDNA expression libraries), involves the immunoscreening
of cDNA libraries prepared from tumor specimens with
autologous sera. So far, over 2,000 candidate TAAs in many
types of human cancer have been identiﬁed and separated
into six categories [5, 8–11]: (1) diﬀerentiation antigens
(expressed by cancers and a restricted subset of normal cells,
e.g., tyrosinase, melan-A/MART-1, NY-BR-1, and gp100),
(2) mutational antigens (e.g., CDK4, β-catenin, caspase-8,
and p53), (3) ampliﬁcation (overexpression) antigens (e.g.,
Her2/neu, NY-C0-58, and p53), (4) splice variant antigens
(e.g.,NY-CO-37/PDZ-45,andING1),(5)viralantigens(e.g.,
HPV and EBV), and (6) cancer-testis (CT) antigens (e.g.,
MAGE, NY-ESO-1, and LAGE-1). The humoral immune
response elicited by TAAs could have two major clinical
applications [9]: (1) AAbs to TAAs could represent novel
biomarkers for cancer diagnosis, prognosis, monitoring, and
prediction of response to chemotherapy, (2) TAAs might
be used as targets for immunotherapy of cancer. Notwith-
standing, eﬀorts to predict cancer based on autoimmunity to
either an individual TAA or even tailor-made panel of TAAs
have not yet resulted in serologic biomarkers with deﬁnitive
predicting speciﬁcity and sensitivity [12]. It has, however,
been shown by some investigators that the use of tailor-made
panel of TAAs, rather than individual TAAs, enhances the
likelihoodofdetectingcancer-associatedAAbswithpotential
diagnostic value [3, 12].
Epithelial ovarian carcinoma is diagnosed in approx-
imately 25,000 women yearly and causes approximately
16,000 deaths each year in the USA, with a worldwide inci-
dence and mortality of approximately 200,000 and 115,000,2 Journal of Oncology
respectively. It is the leading cause of death from gynecologi-
cal malignancies in the USA and is the second leading cause
of death, after uterine cervix cancer, due to gynecological
malignancies in the world [6, 11, 13, 14]. Despite modest
improvements in response rate, progression-free interval,
and median survival due to multimodality treatment includ-
ing cytoreductive surgery and chemotherapy comprised of
platinum compound and paclitaxel, overall survival rates for
epithelial ovarian carcinoma patients remain disappointing
[11]. This has mainly been attributed to lack of early
diagnosis and ineﬀective treatments. More than 75% of
patients diagnosed with epithelial ovarian carcinoma have
an advanced disease (FIGO stage III/IV), which has a ﬁve-
year survival rate of less than 30% [2, 6, 9]. Although
most patients initially respond to chemotherapy, including
complete responses, the relapse rate is ∼85%. Within two
years of cytoreductive surgery and chemotherapy, tumors
usually recur, and once relapse occurs, there is no known
curative therapy. The use of serum-soluble tumor antigens,
such as CA-125 glycoprotein, as biomarkers for detection
of epithelial ovarian carcinoma has been limited by their
insuﬃcient speciﬁcity and sensitivity, particularly for organ-
conﬁned early-stage disease [6, 15]. Elevated levels of CA-
125, the most widely used serum biomarker for epithelial
ovarian carcinoma, occur in only 50% of stage I patients and
can also be detected in healthy women [6, 15].
Recently, a model of surface epithelial ovarian tumors
that includes two main pathways of tumorigenesis corre-
sponding to type I and type II tumors has been proposed
[16–19]. Type I tumors account for 25% of epithelial ovarian
tumors and are made up of low-grade serous carcinomas,
low-grade endometrioid carcinomas, most clear cell carcino-
mas, mucinous carcinomas, and malignant Brenner tumors.
They develop in a stepwise fashion from well-recognized
precursors,namely,borderlinetumorswhichinturndevelop
from benign cystadenomas or adenoﬁbromas. The benign
tumors appear to develop from the ovarian surface epithe-
lium (OSE) or cortical inclusion cysts (CIC) in the case
of serous and mucinous tumors and from endometrio-
sis or endometriomas in the case of endometrioid and
clear cell tumors. Most Type I tumors are slow growing
as evidenced by the observation that they are generally
large and are often conﬁned to the ovary at diagnosis.
Type II carcinomas account for 75% of epithelial ovarian
tumors and include high-grade (“moderately” and “poorly”
diﬀerentiated) serous carcinomas, high-grade endometrioid
carcinomas, few clear cell carcinomas, undiﬀerentiated car-
cinomas, and carcinosarcomas. Type II carcinomas evolve
rapidly, disseminate early in their course, and are highly
aggressive. As these tumors are rarely associated with
morphologically recognizable precursor lesions, it has been
proposed that they develop “de novo” from the OSE or CIC
[16–19]. Although type II carcinomas are rarely associated
with morphologically recognizable precursor lesions, it has
been recently suggested that precursor lesions of type II
carcinomas may arise from dysplasia in inclusion cysts
or serous intraepithelial carcinoma in the fallopian tubes.
These precursor lesions may be diﬃcult to recognize because
they presumably undergo rapid transit from an occult
lesion to a clinically diagnosed overt high-grade carcinoma
[17]. Thus, there is a need to discover novel biomarkers,
such as AAbs to speciﬁc ovarian carcinoma TAAs, for
early diagnosis, prediction of prognosis, and monitoring
of treatment, and to develop new therapeutic approaches,
such as immunotherapy, for the management of this disease
[2, 6, 15].
The establishment of AAbs to TAAs as biomarkers
for epithelial ovarian carcinoma and the development of
successful immunotherapeutic strategies require the iden-
tiﬁcation and characterization of immunogenic epithelial
ovarian carcinoma TAAs that will be recognized by the
host immune system [2, 15]. Barua et al. [6] demonstrated
with use of an enzyme-linked immunosorbent assay (ELISA)
that epithelial ovarian carcinoma patients have signiﬁcantly
higher levels of serum AAbs to proteins extracted from
normal ovarian tissue (P<. 001) and proteins extracted
from ovarian carcinoma tissue (P<. 001) compared to
those of healthy women. The proportion of sera positive
f o rA A b st on o r m a lo v a r i a nt i s s u e( 8 1 % ,P<. 001) and
ovarian carcinoma tissue (69%, P<. 001) was signiﬁcantly
higher in epithelial ovarian carcinoma patients compared
to that of healthy controls [6]. In epithelial ovarian carci-
noma patients, there was no signiﬁcant diﬀerence in AAbs
detection using antigens from normal ovary or from ovarian
carcinoma, and in addition, there was no diﬀerence in
AAbs prevalence by disease stage [6]. Based on these results,
the authors concluded that AAbs to TAAs are a potential
useful diagnostic biomarker for epithelial ovarian carcinoma
[6]. Nevertheless, only few circulating AAbs to speciﬁc
epithelial ovarian carcinoma TAAs have been identiﬁed and
investigated so far [2, 6, 9, 15, 20]. In epithelial ovarian
carcinoma, like in other malignancies, the use of tailor-made
panel of TAAs, rather than individual TAAs, enhances the
likelihoodofdetectingcancer-associatedAAbswithpotential
diagnostic value. By the application of Bayesian modeling of
autologousantibodyresponsesagainstovarianTAAs,Erkanli
et al. [21] demonstrated that measuring speciﬁc AAbs to a
three-member panel of TAAs (p53, NY-CO-8, and HOXB7),
in addition to serum CA-125, yielded a reasonable sensitivity
and speciﬁcity in discriminating between epithelial ovarian
carcinoma patients and healthy controls.
This paper will review the up-to-date knowledge related
to AAbs to TAAs in epithelial ovarian carcinoma. Table 1
shows the frequency of identiﬁed AAbs to epithelial ovarian
carcinoma TAAs.
2.Autoantibodiestop53 Protein
The wild-type p53 gene is a tumor suppressor gene located
on chromosome 17p13 and encodes a 53-kDa nuclear
p h o s p h o p r o t e i nt h a tn o r m a l l ya c t sa sag u a r d i a no ft h e
integrity of the genome and, thus, has been called “guardian
of the genome” [22–25]. p53 gene aberrations are the most
common genetic changes found in human malignancies [22,
23, 26, 27]. Missense point mutations, which represent more
than 85% of gene abnormalities, lead to a conformational
change which stabilizes the p53 protein and allows it to
accumulate in the nucleus to relatively high levels [23, 24,Journal of Oncology 3
26, 28, 29]. Accumulation of the mutant p53 in tumor
cells can elicit a humoral immune response leading to the
production of anti-p53 AAbs [22, 23]. In fact, serum anti-
p53 AAbs were found in 3.5% to 30% of patients with
diﬀerent malignancies and, in particular, in 15% to 29% of
women with ovarian tumor [22–24, 30–32]. Indeed, while
mutation of p53 appears a seminal event in carcinogenesis
and is present in 80% of type II epithelial ovarian carcinoma,
it is still unclear why only a subset (20%–40%) of these
cases generates anti-p53 AAbs [33]. At ﬁrst, it was thought
that only tumors with missense p53 mutations resulting
in p53 overexpression can elicit anti-p53 AAbs [22, 34–
36]. Anti-p53 AAbs have, however, also been detected in
sera from patients with tumors lacking p53 overexpression,
and induction of anti-p53 AAbs in these patients might be
due to the unusual presentation of large amounts of wild-
type p53 from necrotic large tumors or metastases [22, 37].
In recent years, it has been shown that anti-p53 AAbs
are directed against immunodominant epitopes localized in
the amino and carboxy terminal ends of the p53 protein,
unrelated to the mutational hot spot [22, 28, 38–40]. Some
investigatorshavefoundthattumorsbearingp53aberrations
are less sensitive to cisplatin and doxorubicin exposure, and
cisplatin represents the most active compound of standard
chemotherapy regimens in the treatment of epithelial ovar-
ian carcinoma [24, 41, 42]. Because circulating anti-p53
AAbs occur only rarely in individuals with nonmalignant
diseases, it is tempting to speculate that these AAbs are
reliable indicators of malignancy [28]. Ovarian carcinoma
is regarded as a tumor entity associated with the highest
prevalence and titers of circulating anti-p53 AAbs [24, 28,
31]. In other words, ovarian carcinomas are among the
most immunogenic malignancies inducing anti-p53 AAbs
response [28].
Gadducci et al. [43] demonstrated by ELISA that pre-
operative serum anti-p53 AAbs were present in 33% of 30
ovariancarcinomapatients.Angelopoulouetal.[30]showed
with use of a time-resolved immunoﬂuorometric technique
that anti-p53 AAbs were present in 24% of 174 ovarian
carcinoma patients. The presence of anti-p53 AAbs was
related to tumor grade (G1, 5.9%; G2, 38.5%; G3, 27.8%;
P = .001) but not to stage. Univariate analysis showed that
ovarian carcinoma patients with serum anti-p53 AAbs had
signiﬁcantly shorter disease-free survival than those without
anti-p53 AAbs (P = .02) whereas overall survival was
not signiﬁcantly diﬀerent. Multivariate analysis, however,
demonstrated that the presence of anti-p53 AAbs was not
an independent prognostic factor for disease-free survival
o ro v e r a l ls u r v i v a l[ 30]. In another study, Gadducci et al.
[22] investigated with use of a new generation ELISA the
presence of anti-p53 AAbs in blood samples preoperatively
drawn from 86 women with ovarian carcinoma. Serum anti-
p53 AAbs were found in 3 (10.0%) of the 30 women with
stage I/II disease and 15 (26.8%) of 56 women with stage
III/IV disease (P = .09). Forty-four patients with stage
III/IV disease who had six cycles of adjuvant platinum-
based chemotherapy were assessed in detail. A pathological
complete response at second-look surgery was achieved by
none (0%) of the 15 patients with serum anti-p53 AAbs
compared to 7 (24.1%) of the 29 patients without anti-
p53 AAbs (P = .09). The preoperative serum anti-p53
antibody status had no prognostic relevance for overall
survival and progression-free survival. It was concluded
that the assessment of preoperative serum anti-p53 AAbs
seems to have a limited clinical value in the management
of women with advanced-stage epithelial ovarian carcinoma
[22]. Soussi [23] surveyed literature from 1979 through 1999
on anti-p53 AAbs in the sera of patients with various types
of cancer and found 11 studies that examined anti-p53 AAbs
in the sera of ovarian carcinoma patients. The frequency
of anti-p53 AAbs in the sera of ovarian carcinoma patients
ranged in the various studies from 8.7% to 92.3%. Overall,
the presence of anti-p53 AAbs was demonstrated in the sera
of 143/652 (21.9%) ovarian carcinoma patients. With use
of x2 test, it has been shown that the frequency of anti-
p53 AAbs was signiﬁcantly higher in the sera of epithelial
ovarian carcinoma patients compared to that of healthy
individuals (P<10
−4)[ 23]. Only few studies demonstrated
that the presence of anti-p53 AAbs in the sera of ovarian
carcinoma patients was associated with a poor histological
diﬀerentiation [32]a n dp o o rs u r v i v a l[ 30, 44]. Vogl et al.
[38] reported in 1999 that anti-p53 AAbs were identiﬁed
with use of an ELISA in the sera of 38/83 (46%) ovarian
carcinoma patients. Anti-p53 AAbs were detectable at all
stages of disease and were more frequent in patients with
higher age (P = .014), postmenopausal status (P = .050),
and advanced-stage disease (P = .046) [38]. Multivariate
analysis demonstrated that patients with anti-p53 AAbs had
a 1.96-fold risk for relapse (95% conﬁdence interval, 1.02–
3.78) [38]. In 2000, Vogl et al. [28] analyzed with use of
a newly developed ELISA based on highly puriﬁed and
re-natured p53 the presence of anti-p53 AAbs in the sera
of 113 patients with ovarian carcinoma, 15 patients with
borderline ovarian tumor, and 117 patients with benign
ovarian tumor. The prevalence of anti-p53 AAbs in patients
with invasive cancer was 19% (21/113), whereas no anti-
p53 AAbs were found in patients with ovarian borderline
or benign tumors [28]. Anti-p53 AAbs were only detectable
in patients with immunohistochemical staining of nuclear
p 5 3i nt h et u m o r( P = .006). Presence of anti-p53 AAb
positively correlated with tumor stage (P = .034) and
grade (P = .009). Kaplan-Meier analysis showed both a
shortened overall survival (P = .0016) and relapse-free
survival (P = .055) for anti-p53 AAb-positive patients. High
titersofanti-p53AAbsrelatedtoevenworseprognosis.Anti-
p53 AAbs independently related to poor survival adjusting
for stage (P = .026), grade (P = .029), and residual
disease after surgery (P = .005). The authors concluded that
preoperative ﬁndings of adnexal mass with serum anti-p53
AAbsarestronglysuggestiveofanaggressiveinvasiveovarian
cancer [28]. Abendstein et al. [24] evaluated the prognostic
signiﬁcance of preoperative serum and ascitic anti-p53 AAbs
in advanced-stage ovarian carcinoma. In 113 patients with
signiﬁcant amounts of ascites, serum and ascitic anti-p53
AAbs were detected in 28 (24.8%) and 21 (18.6%) patients,
respectively. Univariate analysis showed that detection of
anti-p53 antibodies in ascites, but not in the serum, is a
signiﬁcant predictor of adverse disease-free (P = .003) and4 Journal of Oncology
overall survival (P = .01). Multivariate analysis, however,
demonstrated that ascitic anti-p53 positivity is a signiﬁcant
predictor of only adverse progression-free survival (P = .01)
[24].
With the use of an ELISA, Hogdall et al. [45]d e m o n -
strated preoperative serum IgG anti-p53 AAbs in 24/193
(13%) ovarian carcinoma patients, 0/34 (0%) patients
with ovarian borderline tumors, and 0/86 (0%) healthy
controls. No signiﬁcant associations were demonstrated
between anti-p53 AAbs and clinical stage, age, histological
subtype, and extensiveness of primary surgery. Signiﬁcantly
elevated serum CA-125 levels in anti-p53 AAb-positive
patients compared to lower serum CA-125 levels in anti-
p53 AAb-negative patients (P = .003) were observed. In
univariate and multivariate survival analyses, however, no
signiﬁcant diﬀerences were demonstrated between anti-p53
AAb-positive and anti-p53 AAb-negative ovarian carcinoma
patients [45]. Since a low sensitivity for anti-p53 AAbs alone
and no major additional eﬀect of serum CA-125 level were
demonstrated, it was concluded that serum anti-p53 AAbs
levels are of no diagnostic value, even if combined with the
tumor marker CA-125 [45].
In contrast to the rarity of p53 mutations in type
I tumors, p53 mutations are identiﬁed in 50%–80% of
advanced-stage (stage III and IV) type II epithelial ovarian
carcinomas and in approximately 40% of early-stage (stage
I and II) type II epithelial ovarian carcinomas [16, 18].
This has led to the suggestion that p53 mutation is an early
seminaleventinthedevelopmentoftypeIIepithelialovarian
carcinomas [17]. Moreover, in patients carrying BRCA1 or
BRCA2 germline mutations and, as a result of this, are at
higher risk for ovarian carcinoma, p53 mutations are found
at high frequency, even in very early-stage I high-grade
serous carcinoma identiﬁed upon prophylactic bilateral
salpingo-oophorectomy [33]. Overexpression and mutation
of p53 were observed not only in these microscopic invasive
carcinomas but also in adjacent dysplastic epithelium. Early
serous carcinomas were observed to occur predominantly
in the fallopian tube ﬁmbriae of women with BRCA
germline mutations. Recently, a “p53 signature,” described as
normal tissue morphology but p53 immunostaining positive
(possibly associated with p53 mutation) in the secretory
epithelial cells of the fallopian tube ﬁmbriae, has been
proposed as the precursor of type II carcinomas [14, 46, 47].
The p53 signature is also associated with DNA damage, as
observed using γ-H2AX immunostaining as a biomarker.
Tubal intraepithelial carcinomas are not considered pre-
cursor lesions but rather type II frank malignancies that
will eventually spread if they remain undetected [33]. The
common occurrence of p53 signatures in women with and
without BRCA mutations suggests that it is independent
of BRCA status. However, women at high genetic risk may
be more likely to progress from a p53 signature to an
intraepithelial or invasive carcinoma. It is interesting to note
that women with mutations in BRCA have up to a 46%
lifetime risk of ovarian cancer and that the prevalence of
p53 signatures is 38% in this population, suggesting that in
fact the rate of progression is high [14]. In other words, the
high frequency of p53 signatures in fallopian tubes from all
women, combined with the much higher risk of cancer in
BRCA+ women, suggests that a germline BRCA mutation
may serve as a promoter, enhancing the risk of transition
from a p53 signature to malignancy [46]. Obviously, tests
that detect mutant p53 or autoantibodies to mutant p53
protein in the blood could prove to be useful for detecting
early low-volume type II epithelial ovarian carcinoma [17,
18].
Tsai-Turton et al. [33] demonstrated that serum anti-
p53 AAb levels were signiﬁcantly higher in patients with
type II ovarian carcinoma as compared to those of healthy
women (P<. 001). At a cutoﬀ level of 5.4U/mL, anti-
p53 AAb seropositivity was detected in 25% of the 116 type
II ovarian carcinoma patients, whereas no anti-p53 AAb
seropositivity was seen among the 14 women with type I
ovarian tumor, 20 with atypical proliferative tumors, and 39
with benign ovarian cysts (P<. 0001) [33]. A signiﬁcantly
higher serum anti-p53 AAb level was found in patients with
advanced-stage (III/IV) type II carcinoma as compared to
patients with early-stage (I/II) type II carcinoma (P<. 001).
Type II carcinoma patients whose tumor contained any p53
mutation exhibited signiﬁcantly higher serum anti-p53 AAb
levels than those whose tumor contained only wild-type p53
(P = .0019). There was no obvious association between
mutation in a particular exon and serum anti-p53 AAb
levels [33]. No signiﬁcant correlation was observed between
serum CA-125 levels and serum anti-p53 AAb levels (P =
.8). Of 17 cytokines tested (IL-1β, IL2, IL4, IL5, IL6, IL7,
IL8, IL10, IL12, IL13, IL17, G-CSF, GM-CSF, IFN-γ,M C P -
1 (MCAF), MIP-1β,a n dT N F - α), only the serum levels of
cytokines IL5, IL6, IL-8, IL10, MCP-1, GM-CSF and TNF-
α were signiﬁcantly increased in type II carcinoma patients
as compared to those in healthy women. The serum levels of
IL6, IL-8, and IL10 were also signiﬁcantly elevated in type I
ovarian tumor as compared to those of healthy women. No
signiﬁcant diﬀerences were noted in the plasma levels of each
of the 17 cytokines or CA-125 in ovarian carcinoma patients
with wild type p53 versus mutated p53, with the exception
of IL6 (P = .02) and IL10 (P = .007) that were signiﬁcantly
higherintheseraofthosewithmutatedp53.Anexamination
of correlation was performed between the serum levels of
eachofthe17cytokinesandserumanti-p53AAbsinpatients
with advanced-stage type II carcinoma. Only the absolute
levels of IL4 (P = .019) and IL12 (P = .024) exhibited
a signiﬁcant correlation with the levels of anti-p53 AAbs.
However, upon comparison of cytokine levels and anti-p53
AAb seropositivity at a cutoﬀ level of 5.4U/mL, there was no
correlationwiththelevelsofanycytokine,withtheexception
of IL-8. Women with advanced-stage type II carcinoma
who were also anti-p53 AAb seropositive exhibited lower
serum levels of IL-8 than those of seronegative women
(P = .002) [33]. No association between anti-p53 AAb
seropositivity and survival was observed (P = .29) among
typeIIcarcinomapatients.Likewise,therewasnocorrelation
between any of the 17 cytokine levels tested and the survival
of patients with advanced-stage type II carcinoma. Tsai-
Turton et al.’s conclusions are that [33] (1) type II, but not
type I, ovarian carcinoma patients have elevated serum anti-
p53 AAb levels and (2) anti-p53 AAbs are associated withJournal of Oncology 5
Table 1: Frequency of identiﬁed circulating AAbs to TAAs in epithelial ovarian carcinoma.
A A bt oT A A P o s i t i v e T o t a l % Comment Reference
p53 10 30 33 [43]
p53 42 174 24 Association with shorter disease-free
survival.
[30]
p53 18 86 21 No prognostic relevance for survival. [22]
p53 143 652 22
Summary of 11 studies. Frequency of
AAbs: 8.7%–92.3%. Few studies showed
association with poor histological
diﬀerentiation and poor survival.
[23]
p53 38 83 46 Association with higher risk for relapse. [38]
p53 21 113 19 Correlation with tumor stage and grade.
Association with worse survival.
[28]
p53 28 113 25
Serum AAbs had no prognostic relevance
f o rs u r v i v a l .A s c i t i cA A b sw e r ea s s o c i a t e d
with adverse survival.
[24]
p53 24 193 13
No diagnostic value, even if combined
with CA-125. No prognostic relevance for
survival.
[45]
p53 29 116 25 Detected exclusively in type II carcinoma. [33]
HOXA7 17 48 36 Allows no distinction between benign
and malignant ovarian tumors.
[15]
HOXB7 13 39 33
Signiﬁcant diﬀerence in the frequency of
AAbs between ovarian carcinoma
patients and healthy controls. Promising
diagnostic potential.
[48]
HSP-27 17 34 50 Promising diagnostic potential. Possible
association with improved survival.
[49]
HSP-90 8 32 25 Association with advanced-stage disease.
Promising diagnostic potential.
[9]
Cathepsin D 10 25 40 Promising diagnostic potential. [50]
NY-ESO-1/LAGE-1 NR NR 13 [51]
NY-ESO-1/LAGE-1 11 37 30 No prognostic relevance for survival.
Promising diagnostic potential.
[11]
MUC1 306 668 46 Correlation with a more favorable
prognosis.
[52]
GIPC-1 6 11 54 Promising diagnostic potential. [53]
IL-8 NR 94 NR
Anti-IL-8 AAb levels were elevated in
ovarian carcinoma patients as compared
with those of healthy controls. Promising
diagnostic potential.
[54]
Ep-CAM 22 52 42 Potential diagnostic value. [55]
S100A7 NR 92 NR
Mean AAbs level was signiﬁcantly higher
in ovarian carcinoma patients as
compared to that healthy controls.
Potential diagnostic value.
[2]
NR, not recorded.
mutation of p53, higher plasma IL4, and IL12 but lower
plasma IL-8 levels and no survival advantage.
3.Autoantibodiesto Homeobox Proteins
Homeobox genes are “master control genes” that act at
the top of genetic hierarchies regulating cell growth, dif-
ferentiation, and development [56–58]. Approximately 170
diﬀerent vertebrate homeobox genes have been identiﬁed, of
which 39 belong to the HOX family [56, 57]. Although it is
well established that HOX proteins function as transcription
factors, the vast majority of their targets have yet to be
elucidated. It has been reported that HOXA5 regulates p53
transcription [59] and that p21 is a target of HOXA10
[60]. Expression of cell adhesion molecules is regulated
by several HOX proteins [61]. Auto- and cross-regulatory
interactions within the homeotic network have also been
described [61]. Aberrant HOX gene expression observed6 Journal of Oncology
in various malignancies has implicated their involvement
in neoplasia [56, 57, 61]. The homeobox transcription
factor genes HOXA7, HOXA9, HOXA10, and HOXA11 have
an important role in the morphologic heterogeneity of
epithelialovariancancersandtheirassumptionofmullerian-
like features [58]. Crijns et al. [62] demonstrated that
MEIS and PBX homeobox proteins are extensively expressed
in ovarian carcinomas and may play a role in ovarian
carcinogenesis. Widschwendter et al. [63] demonstrated
that DNA methylation of HOXA9 and HOXA11 genes in
normal endometrium was associated with ovarian cancer.
The overall risk of ovarian cancer was increased 12.3 folds
by high HOXA9 methylation for all stages and 14.8 folds
for early-stage ovarian cancers, independent of age, phase of
the menstrual cycle, and histology of the cancer [63]. It has
been shown that overexpressed and aberrant products of the
homeobox genes in cancer patients can elicit an autologous
immune response.
In contrast to very little or no expression of HOXA7 pro-
tein in normal ovarian surface epithelium (OSE), increased
expression of HOXA7 protein was demonstrated in colum-
nar cells lining invaginations of the OSE, in mullerian-like
epithelium of inclusion cysts of the OSE and in normal
epithelium of the fallopian tube [15]. These observations
raisethepossibilitythatHOXA7expressionisassociatedwith
normal development of the mullerian duct-derived epithelia
and that inappropriate expression of HOXA7 in the OSE
couldgiverisetoaberrantepithelialdiﬀerentiationleadingto
the development of epithelial ovarian carcinoma. Thus, anti-
HOXA7 AAbs represent potential serum biomarkers, par-
ticularly for detecting small, early-stage ovarian carcinomas
[15]. With use of an ELISA employing puriﬁed recombinant
HOXA7 protein, Naora et al. [15] detected anti-HOXA7
AAbs in the sera of 1/24 (4.1%) patients with poorly diﬀer-
entiated ovarian serous carcinoma, 16/24 (66.6%) patients
with well-to moderately diﬀerentiated ovarian serous carci-
noma, 13/19 (68.4%) patients with benign ovarian serous
cystadenoma, and 0/30 (0%) healthy women. These ﬁndings
indicate that an obvious deﬁciency in the utility of serum
anti-HOXA7 AAbs as a diagnostic biomarker is its extremely
poor sensitivity for detecting poorly diﬀerentiated ovarian
carcinomas [15]. Nevertheless, although the anti-HOXA7
AAb assay alone allows no distinction between benign and
malignant ovarian tumors, it is able to discriminate patients
with well-to moderately diﬀerentiated ovarian carcinomas
from healthy women [15].
Ovarian carcinomas were found to express HOXB7, a
product of a homeobox gene, at markedly higher levels
than normal OSE [21, 48]. Overexpression of HOXB7 in
immortalized normal OSE cells upregulated expression of
basic ﬁbroblast growth factor (bFGF), a potent mitogenic
and angiogenic factor and dramatically increased OSE
cell proliferation [21, 48]. This indicates that HOXB7
overexpression could play a signiﬁcant role in growth of
ovarian carcinomas. Naora et al. [48] revealed signiﬁcant
serologic reactivity to the HOXB7 antigen in 13/39 (33.3%)
of ovarian carcinoma patients and in only 1/29 (3.4%) of
healthy women (P<. 0001). This preliminary observa-
tion needs to be validated in larger case-control studies
with particular attention being drawn to correlating titers
of anti-HOXB7 AAbs with stage of disease. Nevertheless,
Naora et al.’s data raise the possibility that serologic detec-
tion of anti-HOXB7 AAbs could have diagnostic potential
[48].
4.AutoantibodiestoHeatShockProteins
By ELISA using a puriﬁed recombinant 27-kd heat shock
protein (HSP-27), Korneeva et al. [49]d e m o n s t r a t e da
signiﬁcantly higher prevalence of serum IgG AAbs to HSP-
27 in patients with ovarian carcinoma (17/34, 50%) and
other female genital tract malignancies compared to those in
healthy women (3.4%). AAbs to other heat shock proteins
(HSP-60, HSP-70, and HSP-90) were also detected in some
patients with female genital tract malignancies, including
ovarian carcinoma, but their prevalence was not diﬀerent
from that found in healthy controls [49]. Thus, HSP-27
appears to be uniquely autoantigenic after development of
cancer of the female genital tract and may therefore be a
marker for the presence of cancer of the female genital tract.
Since the presence of AAbs to HSP-27 has been associated
withanimprovedsurvivalamongpatientswithbreastcancer,
it has been speculated that these AAbs may directly aid in
the immune defense against cancer [49]. Another possibility,
as suggested by Conroy et al. [64], is that autoimmunity to
HSP-27isnotdirectlyassociatedwithsurvival.Instead,HSP-
27 may be a surrogate marker for immunity to a TAA that
is bound to this heat shock protein [64]. Further studies on
autoimmunity to HSP-27 and characterization of HSP-27-
TAA complexes could lead to new methodologies to boost
immune defenses against cancer [64].
With use of SEREX, Luo et al. [9] identiﬁed 12 new
candidate ovarian carcinoma antigens. One of them, heat
shock protein 90 (HSP-90), was studied in detail and
found to be immunogenic in one-third of the patients
with advanced-stage ovarian carcinoma. Anti-HSP-90 AAbs
were detected in the sera of 7/22 (32%) patients with stage
III/IV ovarian carcinoma, 1/10 (10%) patients with stage
I/II ovarian carcinoma, 1/37 (2.7%) colorectal carcinoma
patients, 1/13 (7.7%) breast carcinoma patients, and 1/20
(5%) patients with benign gynecologic disease [9]. Based
on the ﬁnding that anti-HSP-90 AAbs are frequently found
in advanced-stage epithelial ovarian carcinoma, it has been
concluded that anti-HSP-90 AAbs might represent a novel
biomarker for epithelial ovarian carcinoma and that HSP-90
might be used as a target for immunotherapy in this disease
[9].
5.Autoantibodiesto CathepsinD
Primarybiologicalfunctionofenzymaticallyactivecathepsin
D is protein degradation in an acidic milieu of lysosomes
[65]. Failure of this function resulted in accumulation
of lipofuscin in variety of cell types, neurodegeneration,
developmental regression, and visual loss. Procathepsin D,
secreted from cancer cells, acts as a mitogen on both
cancer and stromal cells and stimulates their proinvasive andJournal of Oncology 7
prometastatic properties. Procathepsin D/cathepsin D levels
represent an independent prognostic factor in a variety of
cancers [65].
Both52-kDaprocathepsinDand32-kDamaturecathep-
sin D were shown to elicit a humoral immune response in
epithelial ovarian carcinoma patients [50, 66]. No signiﬁcant
diﬀerence was detected in the immunoreactivity of patient
serum with the glycosylated and deglycosylated forms of
the cathepsin D, suggesting that patient humoral responses
are directed primarily against the core protein [50, 66].
Four immunogenic epitopes of cathepsin D were identiﬁed:
two peptides within the procathepsin D, the third at the
carboxy terminus, and the fourth at the glycosylation site
of the mature enzyme [50, 66]. The identiﬁcation of speciﬁc
antigenic epitopes of cathepsin D may be useful in deﬁning
eﬀective targets for directed active immunotherapy for
epithelial ovarian carcinoma. Three mechanisms leading to
the generation of AAbs to cathepsin D in epithelial ovarian
carcinoma patients have been identiﬁed: overexpression
of cathepsin D resulting from ampliﬁcation or increased
protein stability, altered glycosylation of cathepsin D at
amino acid 134, and inappropriate extracellular release
of cathepsin D [50, 66]. Chinni et al. [50] found that
10/25 (40%) epithelial ovarian carcinoma patients produced
circulating AAbs to cathepsin D. It has been concluded
that identifying TAAs that elicit humoral immune response
and deﬁning antigenic epitopes may provide new avenues
for depicting antigenic targets for directed immunotherapy
[50, 66]. Recently, Taylor et al. [67] showed that the presence
of AAbs against cathepsin D can diﬀerentiate between
benign ovarian masses and ovarian carcinomas (even stage I
carcinoma).
6. Autoantibodiesto Cancer-Testis Antigens
The cancer-testis (CT) antigens are a distinct and unique
class of diﬀerentiationantigensthatareexpressedinavariety
of cancers, but not in normal adult tissues, except for germ
cells of the testis, and hence appear to be ideal targets for
immunotherapy [10, 11, 68]. The NY-ESO-1 or LAGE-1
antigens belong to the group of CT antigens. The NY-ESO-
1g e n ei sl o c a t e do nX q 2 8[ 9]. Stockert et al. [51]r e p o r t e d
an AAb response to NY-ESO-1/LAGE-1 antigen in 12.5%
of epithelial ovarian carcinoma patients. Odunsi et al. [11]
showed that serum AAbs to CT antigens NY-ESO-1 and
LAGE-1 were detected in 11/37 (30%) epithelial ovarian
carcinoma patients whose tumors expressed either NY-ESO-
1 or LAGE-1 antigens. Detectable AAbs were present for
up to 3 years after initial diagnosis of epithelial ovarian
carcinoma. Although there was no statistically signiﬁcant
association between NY-ESO-1/LAGE-1 antigens expression
and patients’ survival, the data showed aberrant expression
of NY-ESO-1 and LAGE-1 in a signiﬁcant proportion of
epithelial ovarian carcinoma patients [11]. These ﬁndings
indicate that AAbs to NY-ESO-1 and LAGE-1 antigens might
serve as a biomarker of epithelial ovarian carcinoma and
that NY-ESO-1 and LAGE-1 antigens are attractive targets
for antigen-speciﬁc immunotherapy in epithelial ovarian
carcinoma [11].
7. Autoantibodiesto MUC1 Protein
Polymorphic epithelial mucin (PEM, MUC1), a human
mucin family member, is a high-molecular-weight (over
400kDa) transmembrane glycoprotein. It is expressed in a
hyperglycosylated form and low levels by many types of
normal epithelial cells and in a hypoglycosylated form and
high levels by most epithelial adenocarcinomas including
ovarian and breast carcinomas [52, 69]. About one-third of
ovarian and breast carcinoma patients have circulating AAbs
to MUC1, either free or bound to immune complexes. While
the presence of these immune complexes has prognostic
signiﬁcance in cancer patients, the signiﬁcance of free AAbs
to MUC1 is less clear [70]. AAbs to MUC1 have been
described and correlated with a more favorable prognosis;
thus,itseemsthatriskforepithelialovariancarcinomamight
bereducedbypreexisting MUC1-speciﬁcimmunity [71,72].
With use of an ELISA, Cramer et al. [52] investigated the
presence of anti-MUC1 AAbs in the sera of 668 epithelial
ovarian carcinoma patients. By a cutoﬀ of optical density
(OD) ≥ 0.6, 33.8% of controls and 45.8% of epithelial
ovarian carcinoma patients were positive for anti-MUC1
AAbs. By a cutoﬀ of OD ≥ 1.0, 12.3% of controls and 25% of
ovarian carcinoma patients had a high level of anti-MUC1
AAbs. The authors found that factors known to decrease
the risk of developing epithelial ovarian carcinoma, such as
oral contraceptive use and nonuse of talc in genital hygiene,
are associated with presence of circulating anti-MUC1 AAbs
[52]. This supports the notion that preexisting AAbs to
MUC1 may reduce the risk of developing epithelial ovarian
carcinoma, and presence of AAbs to MUC1 in epithelial
ovarian carcinoma is correlated with a more favorable
prognosis [52].
8.Autoantibodiesto GIPC-1Protein
The protein known as GIPC-1, a member of a family of
PDZ-domain conserved proteins, is involved in regulation
of G-protein signaling and is upregulated in ovarian and
breast carcinomas [53, 73–75]. With use of 27.B1 and 27.F7
human monoclonal antibody speciﬁc to GIPC-1 protein,
Yavelsky et al. [53] demonstrated, respectively, a positive
immunnohistochemical staining for GIPC-1 in 7/13 (54%)
and 8/15 (53%) of ovarian serous carcinomas, 4/11 (36%)
a n d0 / 1 1( 0 % )o fo v a r i a nb o r d e r l i n es e r o u st u m o r s ,2 / 1 5
(14%) and 3/15 (21%) of ovarian serous cystadenomas, and
0/8 (0%) and 0/8 (0%) of normal ovarian tissues. Based
on these results, the authors [53] hypothesize that detection
of serum AAbs to GIPC-1 might be a sensitive marker
for early-stage epithelial ovarian carcinoma and superior to
methodologies based on TAA detection. With use of a novel
technique of chemiluminescent optical ﬁber immunoassay
(the instrument is called chemiluminescent optical ﬁber
immunosensor), Salama et al. [75]t e s t e ds e r af r o m1 1
epithelial ovarian carcinoma patients, 22 breast carcinoma
patients, and asymptomatic controls for the presence of
IgM anti-GIPC-1 AAbs. The chemiluminescent optical ﬁber
immunosensor detected 54% and 77% anti-GIPC-1 AAbs-
positive sera within ovarian and breast carcinoma patients,8 Journal of Oncology
respectively, as compared to ELISA, which only detected 18%
and 27%, respectively [75]. The authors conclude that the
chemiluminescent optical ﬁber immunoassay is an eﬃcient
technique for prompt detection of AAbs to TAAs and, thus,
foresee that the newly developed chemiluminescent optical
ﬁber immunosensor might serve as an eﬃcient tool for early
diagnosis of ovarian and breast carcinomas [75].
9.AutoantibodiestoIL-8
IL-8 belongs to the superfamily of CXC chemokines attract-
ingneutrophilsandmacrophagesandmanifestsawiderange
of proinﬂammatory eﬀects. In addition, IL-8 was found to
be a potent proangiogenic factor and is able to promote
tumor cell proliferation, modulate collagenase production,
and aﬀect metastasis formation. IL-8 is produced by various
malignant cells, and increased blood levels of IL-8 have
beendemonstratedinseveralmalignanciesincludingovarian
cancer [54]. Recently, Tsai-Turton et al. [33] showed that
women with advanced-stage type II ovarian carcinoma who
were also anti-p53 AAb seropositive exhibited lower serum
levels of IL-8 than seronegative cases (P = .002). With
use of an immunoﬂuorescent bead-based assay, Lokshin et
al. [54] measured circulating IL-8 and anti-IL-8 IgG AAbs
in sera from 44 patients with early-stage (I-II) epithelial
ovarian carcinoma, 50 patients with advanced-stage (III-IV)
epithelial ovarian carcinoma, 37 patients with benign pelvic
masses, and 80 healthy women. Concentrations of serum
anti-IL-8 IgG AAbs in epithelial ovarian carcinoma patients
variedfrom2.8to250.7ng/mL.Meanconcentrationsofanti-
IL-8 IgG AAbs were signiﬁcantly higher in patients with
both early-stage (I-II) (P<. 01) and advanced-stage (III-
IV) (P<. 05) epithelial ovarian carcinomas as compared
with healthy controls but were also elevated in the sera
of patients with benign pelvic masses. Anti-IL-8 IgG AAbs
concentrations did not diﬀer signiﬁcantly between patients
withearly(I-II)versuslate(II–IV)stagesofepithelialovarian
carcinoma. However, when concentrations of anti-IL-8 IgG
AAbs were analyzed in a group of patients with only stage I
epithelial ovarian carcinoma, the diﬀerences between cancer
and control group did not reach statistically signiﬁcant
levels [54]. Logistic regression analysis of concentrations
of anti-IL-8 IgG AAbs in patients with stages I and II
epithelial ovarian carcinoma versus healthy controls allowed
forpredictionofearlyepithelialovariancarcinomawith98%
speciﬁcity and 65.5% sensitivity. Combining IL-8 and anti-
IL-8 IgG AAbs with CA-125 resulted in increased classiﬁ-
cation power as compared to individual markers analyzed
separately. The authors concluded that IL-8 and anti-IL-8
AAbs might potentially serve as additional biomarkers for
epithelial ovarian carcinoma [54].
10.Autoantibodiesto Ep-CAM
Epithelial cell adhesion molecule (Ep-CAM) is a ubiquitous
antigen in epithelial cells that is highly overexpressed in
epithelial ovarian carcinoma as well as other cancers, and its
expression is correlated with malignant proliferation [55].
W i t hu s eo fa nE L I S A ,K i me ta l .[ 55] examined AAbs to
Ep-CAM in sera of 52 epithelial ovarian carcinoma patients,
26 patients with benign ovarian disease, and 26 normal
controls. The mean optic density (OD) levels of AAbs to
Ep-CAM in cancer patients, benign ovarian disease, and
normal controls were 0.132, 0.098, and 0.090, respectively.
The diﬀerence between cancer cases and the other cases
was statistically signiﬁcant (P<. 05). The sera of stage IV
epithelial ovarian carcinomas showed lower levels of AAbs
to Ep-CAM, compared with either stage I or II epithelial
ovarian carcinomas (P<. 05). Based on OD cutoﬀ value
0.140 for AAbs to Ep-CAM, which was deﬁned as the mean
OD value of the normal controls +2 standard deviations
(SD), 22 epithelial ovarian carcinoma patients (42.3%) were
positive, whereas none of the control (0%) and 2 benign
ovarian disease (7.7%) cases were positive [55]. A receiver
operatingcurve(ROC)wasplottedtoinvestigatetheoptimal
OD cutoﬀ value and to compare AAbs to Ep-CAM with
CA-125. Based on OD cutoﬀ v a l u eo f0 . 1 1 5f o rA A b st o
Ep-CAM, 38 (73.1%) epithelial ovarian carcinoma patients
were positive, whereas 6 (23.1%) benign ovarian disease
cases and 5 (19.2%) normal cases were positive [55]. Thus,
an OD cutoﬀ value of 0.115 enabled AAbs to Ep-CAM to
detect epithelial ovarian carcinoma with 73.1% sensitivity
and 80.8% speciﬁcity. In comparison, with the use of a
cutoﬀ value 35units/mL, CA-125 detected epithelial ovarian
carcinoma with 86.5% sensitivity and 88.5% speciﬁcity.
By using both AAbs to Ep-CAM and CA-125, epithelial
ovarian carcinoma was detected with 90.4% sensitivity and
92.3% speciﬁcity [55]. It was concluded that although AAbs
to Ep-CAM are less sensitive and speciﬁc than CA-125,
AAbs to Ep-CAM might be complementary to CA-125. By
combining AAbs to Ep-CAM with CA-125, the speciﬁcity is
increased as compared with CA-125 alone without lowering
the sensitivity. This means that the false positive ratio can
be decreased by way of combining AAbs to Ep-CAM with
CA-125 in screening and early diagnosis of epithelial ovarian
carcinoma [55].
11.Autoantibodiesto S100A7
By using the technique of two-dimensional diﬀerential
gel electrophoresis analysis of immunoprecipitated tumor
antigens (2D-DITA), Gagnon et al. [2] identiﬁed signiﬁ-
cantly higher expression of S100A7 protein (11-kDa protein
expressed by a wide variety of cells and is involved in the
regulation of cell cycle progression and diﬀerentiation) in
epithelial ovarian carcinoma tissue compared to that in
normal ovary. In addition, they identiﬁed by an ELISA
signiﬁcantly elevated levels of AAb to S100A7 protein in the
plasma of epithelial ovarian carcinoma patients compared
with those of healthy controls. Since signiﬁcantly higher
levels of S100A7 expression were observed in both early- and
advanced-stage epithelial ovarian carcinoma compared with
those benign and normal ovarian tissues, the authors [2]
suggest that (1) increased S100A7 expression may be an early
event in ovarian pathogenesis and (2) AAbs to S100A7 may
serve as a useful biomarker for early diagnosis of epithelial
ovarian carcinoma.Journal of Oncology 9
12. Conclusion
Epithelial ovarian carcinoma is highly lethal because it
is typically asymptomatic until well advanced. Traditional
diagnostic tools for early diagnosis of epithelial ovarian
carcinoma, that is, manual pelvic examination, imaging
studies (US, CT, MRI, PET, etc.), and measurement of serum
CA-125 levels, are crippled with insuﬃcient sensitivity and
speciﬁcity [2, 6, 68]. Thus, at present, there is little to
oﬀer for early diagnosis of epithelial ovarian carcinoma.
AAbs to TAAs have been shown to be present in the
circulation of people with various forms of solid tumor
even before TAAs can be detected, and these AAbs can
be measured up to 5 years before symptomatic disease [2,
68, 76, 77]. Thus, evidently, the human immune system
recognizes the autologous TAAs as “nonself” and makes a
humoral immune response very early in the disease process
[2]. Although measurement of AAbs to a single TAA is
possible, the low sensitivity and speciﬁcity renders single
AAb measurements of little value for screening and early
detection of cancer. There has been some proof, however,
that combination of AAbs to various TAAs into a panel
assay test might provide a reasonable level of sensitivity and
speciﬁcity for the detection of cancer [2, 4, 6, 21, 76–78].
Thus, preliminary data support the idea of developing a
serum assay evaluating the antibody response to a panel of
TAAsforcancerdiagnosis[1].Theimplicationsofthiswould
be that AAbs to TAAs would provide a simple blood test
for early diagnosis of epithelial ovarian carcinoma [2, 6].
Nevertheless, it must be remembered that measurement of
serum AAbs to TAAs for early diagnosis of epithelial ovarian
carcinoma is still investigational and should be carried out
along with traditional diagnostic studies.
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